DUPIXENT has a demonstrated long-term safety profile, including patients as young as 6 months of age, that’s supported by clinical data. The safety profile of DUPIXENT through Week 16 (in pivotal trials) and Week 52 (in an open-label extension trial, AD-1434) observed in pediatric patients aged 6 months to 17 years was consistent with that seen in adults with AD. In AD-1434, hand-foot-and-mouth disease and skin papilloma (incidence ≥2%) were reported in patients 6 months to 5 years of age. These cases did not lead to study drug discontinuation.1
See more information on DUPIXENT safety